Literature DB >> 16196523

Passive seeding in metanephric adenoma: a review of pseudometastatic lesions in perinephric lymph nodes.

Gladell P Paner1, Thomas M Turk, Joseph I Clark, Valerie Lindgren, Maria M Picken.   

Abstract

Lymph node involvement derived from a discrete neoplastic process fundamentally implies tumor malignancy. However, rarely, inconsequential passive transport of benign neoplastic cells to the lymph node can occur and may cause confusion as to the nature of the neoplasm (ie, malignant vs benign). We describe a 10-cm right renal metanephric adenoma incidentally discovered in a 30-year-old woman during cesarean section for a triplet pregnancy. Subsequent nephrectomy following an equivocal needle biopsy diagnosis showed histologic features classic for metanephric adenoma, including the lack of cytologic atypia and mitoses. Necrosis present in this lesion appeared to be secondary to tumor physical disruption. The tumor cells were positive for Wilms tumor 1 (WT1) antigen, pankeratin, and CD57, focally positive for epithelial membrane antigen, and negative for cytokeratin 7, cytokeratin 34betaE12, and CD56. Electron microscopy confirmed the tumor's epithelial nature, and cytogenetics revealed a diploid 46XX karyotype. The tumor proliferation index with Ki-67 was only 3% to 5% and the proliferating cell nuclear antigen index was 0%. A single, concurrently resected hilar lymph node contained scattered subcapsular, sinusoidal, and focally intralymphovascular psammoma bodies along with occasional adherent epithelial cells. These cells were highlighted by pankeratin but were nonreactive to WT1 antigen, similar to the nonviable cells in the primary tumor. Clinical surveillance and follow-up showed no disease recurrence 4 years after nephrectomy. We postulate that the lymph node inclusions found in this case represent passive transport of neoplastic cells to the lymph node following manipulation of the renal mass. We conclude that this phenomenon is understudied and underrecognized and can easily be mistaken for metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16196523     DOI: 10.5858/2005-129-1317-PSIMAA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  BRAF mutations in metanephric adenoma of the kidney.

Authors:  Toni K Choueiri; John Cheville; Emanuele Palescandolo; André P Fay; Philip W Kantoff; Michael B Atkins; Jesse K McKenney; Victoria Brown; Megan E Lampron; Ming Zhou; Michelle S Hirsch; Sabina Signoretti
Journal:  Eur Urol       Date:  2012-06-09       Impact factor: 20.096

2.  Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases.

Authors:  Ying Ding; Cong Wang; Xuejie Li; Yangyang Jiang; Ping Mei; Wenbin Huang; Guoxin Song; Jinsong Wang; Guoqiang Ping; Ran Hu; Chen Miao; Xiao He; Gang Chen; Hai Li; Yan Zhu; Zhihong Zhang
Journal:  Diagn Pathol       Date:  2018-08-16       Impact factor: 2.644

3.  Immunohistochemical phenotype and molecular pathological characteristics of metanephric adenoma.

Authors:  Zhulei Sun; Shihai Kan; Leilei Zhang; Yan Zhang; Hong Jing; Gui Huang; Qichun Yu; Jiang Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

4.  The Clinical Characteristics of Metanephric Adenoma: A Case Report and Literature Review.

Authors:  Hua Fan; Qian-Qian Shao; Han-Zhong Li; Yu Xiao; Yu-Shi Zhang
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.